Testing effectiveness (Phase 2)UnknownNCT01676558
What this trial is testing
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma
Korea Cancer Center Hospital 24